E. Reines

发表

The cardiovascular safety profile of escitalopram

M. Thase, S. Kennedy, K. Larsen, 2013, European Neuropsychopharmacology.

Escitalopram Therapy for Major Depression and Anxiety Disorders

E. Weiller, D. Baldwin, E. Reines, 2007, The Annals of pharmacotherapy.

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

M. Papp, S. Montgomery, C. Sánchez, 2001, Pharmacology & toxicology.

Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.

D. Baldwin, E. Reines, S. Schmidt, 2022, Journal of affective disorders.

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

D. Baldwin, G. Nomikos, I. Florea, 2016, Journal of psychopharmacology.

Depression in primary care patients: Improvement during long-term escitalopram treatment

N. Despiégel, A. Wade, E. Reines, 2002, European Neuropsychopharmacology.

Management of Depression in Adolescents in Japan.

Takuya Saito, I. Florea, E. Reines, 2019, Journal of child and adolescent psychopharmacology.

Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials

J. Affinito, A. Mahableshwarkar, E. Reines, 2019, CNS Spectrums.

A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?

S. Montgomery, C. Sánchez, E. Reines, 2014, International clinical psychopharmacology.

Escitalopram versus citalopram: the surprising role of the R-enantiomer

K. Bogeso, C. Sánchez, C. Braestrup, 2004, Psychopharmacology.

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder

K. Demyttenaere, H. Andersen, E. Reines, 2008, International clinical psychopharmacology.

Patient Response Trajectories in Major Depressive Disorder.

M. Thase, S. Kennedy, K. Larsen, 2020, Psychopharmacology bulletin.

A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*

L. Colonna, H. Andersen, E. Reines, 2005, Current medical research and opinion.

Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care

U. Lepola, H. Loft, E. Reines, 2003, International clinical psychopharmacology.

Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo

D. Baldwin, K. Larsen, Satoshi Asakura, 2016, European Neuropsychopharmacology.

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea

Jee Wook Kim, S. Moon, E. Reines, 2023, Frontiers in Psychiatry.

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

U. Lepola, H. Loft, E. Reines, 2003 .

Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis.

K. Demyttenaere, M. Lader, S. Lönn, 2011, The primary care companion for CNS disorders.

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

U. Lepola, H. Loft, A. Wade, 2002, International clinical psychopharmacology.

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder

K. Demyttenaere, H. Andersen, E. Reines, 2008, International clinical psychopharmacology.

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

G. Wang, Ping Guo, Jingdong Ma, 2022 .

Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies

G. Mattingly, E. Reines, S. Schmidt, 2023, Current medical research and opinion.

Goal setting and goal attainment in patients with major depressive disorder: a narrative review on shared decision making in clinical practice

E. Reines, Daniel Oudin Åstrøm, David S Baldwin, 2024, Current Medical Research and Opinion.

Escitalopram is efficacious and well tolerated in the treatment of depression in primary care

U. Lepola, E. Reines, Henrik Loft, 2002, European Neuropsychopharmacology.